Lipella Pharmaceuticals Inc. (LIPO)

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company founded in 2005 and based in Pittsburgh, Pennsylvania. Its approach was to reformulate existing generic drugs for new uses and delivery routes, aiming to improve effectiveness and safety for specific patient groups. The company's work grew out of academic research in Pittsburgh on drug delivery to the bladder and other mucosal tissues.

Its lead candidate, LP-10, is a liposomal formulation of tacrolimus given directly into the bladder. It was studied in a Phase 2a trial for hemorrhagic cystitis caused by radiation, a condition with limited treatment options. A second program, LP-310, is an oral formulation of tacrolimus developed for oral lichen planus, a chronic inflammatory disease of the mouth.

Lipella's strategy of reformulating established active ingredients was intended to shorten development timelines and use known safety data. The company also received grant funding to support certain development work. As a company without product revenue, it depended on capital markets and grants to fund its clinical trials and operating costs.

Lipella completed an initial public offering in December 2022 and listed its common stock on the Nasdaq Capital Market under the symbol LIPO. In 2024 it ran into trouble meeting Nasdaq's continued listing requirements, including the minimum stockholders' equity rule. On October 16, 2024, Nasdaq staff issued a determination, and the company appealed to a Listing Qualifications Hearings Panel, which held a hearing on December 12, 2024.

The company arranged offerings with an investor to regain compliance with the equity standard. Nasdaq later concluded that the structure of the securities issued in those transactions violated its shareholder approval and voting rights rules, Listing Rules 5635(d) and 5640. A new staff determination followed in May 2025 on those grounds.

On June 17, 2025, the panel decided to delist the company, stating that it had not been persuaded the problem was unintentional and saw no basis to grant more time. Trading in the common stock was suspended at the open on June 20, 2025, following the June 19 market holiday. The delisting determination became final on August 1, 2025.

The removal from listing and registration took effect on October 16, 2025, based on the exchange's notice to the Securities and Exchange Commission. The delisting was a result of exchange rule violations and not of an acquisition. The company issued a letter to stockholders after the suspension discussing its plans going forward.